Silence Therapeutics (LON:SLN)‘s stock had its “buy” rating reissued by research analysts at Peel Hunt in a research report issued on Thursday. They presently have a GBX 275 ($3.68) price target on the stock. Peel Hunt’s target price points to a potential upside of 38.67% from the stock’s current price.
Shares of Silence Therapeutics (LON:SLN) opened at GBX 198.31 ($2.65) on Thursday. The firm has a market capitalization of $142.61 and a PE ratio of -1,525.46. Silence Therapeutics has a one year low of GBX 71.88 ($0.96) and a one year high of GBX 254.75 ($3.41).
COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/28/silence-therapeutics-sln-rating-reiterated-by-peel-hunt.html.
About Silence Therapeutics
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.